Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment

BACKGROUND AND PURPOSE: As a third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib is approved for treating advanced non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation after progression on first- or second-generation EGFR-TKIs such as gefitinib, erlotinib and afatinib....

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xin, Li, Yuan, Yan, Wei-feng, Qian, Wen-lei, Pang, Tong, Gong, You-ling, Yang, Zhi-gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511497/
https://www.ncbi.nlm.nih.gov/pubmed/34660285
http://dx.doi.org/10.3389/fonc.2021.719919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511497/
https://www.ncbi.nlm.nih.gov/pubmed/34660285
http://dx.doi.org/10.3389/fonc.2021.719919

Ejemplares similares